Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

More articles from Articles

  • Selenite-induced p53 Ser-15 phosphorylation and caspase-mediated apoptosis in LNCaP human prostate cancer cells
    Cheng Jiang, Hongbo Hu, Barbara Malewicz, Zaisen Wang, Junxuan Lü
    Molecular Cancer Therapeutics Jul 2004, 3 (7) 877-884;
  • Involvement of base excision repair in response to therapy targeted at thymidylate synthase
    Li Li, Sondra H. Berger, Michael D. Wyatt
    Molecular Cancer Therapeutics Jun 2004, 3 (6) 747-753;
  • Identification of 4-anilino-3-quinolinecarbonitrile inhibitors of mitogen-activated protein/extracellular signal-regulated kinase 1 kinase
    Robert Mallon, Larry Feldberg, Steven Kim, Karen Collins, Donald Wojciechowicz, Constance Kohler, Diana Kovacs, Carolyn Discafani, Nan Zhang, Biqi Wu, Brawner Floyd, Dennis Powell, Dan Berger
    Molecular Cancer Therapeutics Jun 2004, 3 (6) 755-762;
  • Transcriptional targeting in renal cancer cell lines via the human CXCR4 promoter
    Yosef S. Haviv, Winan J. van Houdt, Baogen Lu, David T. Curiel, Zeng B. Zhu
    Molecular Cancer Therapeutics Jun 2004, 3 (6) 687-691;
  • The p65 subunit of nuclear factor-κB is a molecular target for radiation sensitization of human squamous carcinoma cells
    Kyoung M. Kim, Yin Zhang, Bo-Yeon Kim, Sook J. Jeong, Sung A. Lee, Gun-Do Kim, Anatoly Dritschilo, Mira Jung
    Molecular Cancer Therapeutics Jun 2004, 3 (6) 693-698;
  • X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells
    Adams Amantana, Carla A. London, Patrick L. Iversen, Gayathri R. Devi
    Molecular Cancer Therapeutics Jun 2004, 3 (6) 699-707;
  • Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation
    Jie Liu, Chengxiu Li, Wei Qu, Elaine Leslie, Challice L. Bonifant, Gregory S. Buzard, Joseph E. Saavedra, Larry K. Keefer, Michael P. Waalkes
    Molecular Cancer Therapeutics Jun 2004, 3 (6) 709-714;
  • Aryl hydrocarbon receptor activation of an antitumor aminoflavone: Basis of selective toxicity for MCF-7 breast tumor cells
    Andrea I. Loaiza-Pérez, Susan Kenney, Jamie Boswell, Melinda Hollingshead, Michael C. Alley, Curtis Hose, Henry P. Ciolino, Grace C. Yeh, Jane B. Trepel, David T. Vistica, Edward A. Sausville
    Molecular Cancer Therapeutics Jun 2004, 3 (6) 715-725;
  • Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-κB dependent
    Jiabin An, Yiping Sun, Myrna Fisher, Matthew B. Rettig
    Molecular Cancer Therapeutics Jun 2004, 3 (6) 727-736;
  • SB-431542, a small molecule transforming growth factor-β-receptor antagonist, inhibits human glioma cell line proliferation and motility
    Mark D. Hjelmeland, Anita B. Hjelmeland, Sith Sathornsumetee, Elizabeth D. Reese, Michael H. Herbstreith, Nicholas J. Laping, Henry S. Friedman, Darell D. Bigner, Xiao-Fan Wang, Jeremy N. Rich
    Molecular Cancer Therapeutics Jun 2004, 3 (6) 737-745;

Pages

  • Next
  • 1
  • 2
  • 3
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement